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Chronic obstructive pulmonary disease
(COPD) is defined as a disorder characterised by
expiratory airflow limitation that is not fully re-
versible [1]. The airflow limitation is usually slowly
progressive and associated with an inflammatory
response of the lungs to noxious particles or gases.
The airflow obstruction may be caused by struc-
tural alterations and/or functional factors. COPD,
related in most cases to extensive cigarette smok-
ing, is a leading cause of chronic morbidity and
mortality among patients over 55.
Over the past ten years several guidelines for
the assessment and management of COPD have
been published [2–5]. Our new guidelines are
based on those published in 1997 [6], the GOLD
report (Global initiative on chronic Obstructive Lung
Disease), a collaborative project of the U.S. Na-
tional Heart, Lung and Blood Institute and the
World Health Organisation, and an extensive re-
view of the pertinent literature. Following the re-
quirements of evidence-based medicine, we used
the system for assigning levels of evidence to the
statements made throughout the present report
(table 1) [7].
The goal of these guidelines is to advise pul-
monary physicians, general practitioners and other
health care workers on the early detection, diag-
nosis and prevention of COPD, the best sympto-
matic control of the disease, and the avoidance of
complications and deterioration of COPD. 
Definition
The terms chronic bronchitis and emphysema
are no longer included in this working definition
of COPD. Chronic bronchitis is a clinical and epi-
demiological term (i.e. cough and mucus produc-
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Introduction
Evidence category sources of evidence definition
A Randomised controlled Evidence is from endpoints of well-designed RCTs that provide a consistent 
trials (RCT). Rich body pattern of findings in the population for which the recommendation is made. 
of data. Category A therefore requires substantial numbers of studies involving substantial 
numbers of participants.
B Randomised controlled trials Evidence is from endpoints of intervention studies that include only a limited 
(RCT). Limited body of data. number of RCTs, posthoc or subgroup analysis of RCTs, or metaanalysis of RCTs.
Category B pertains when few randomised trials exist, they are small in size, 
the trial results are somewhat inconsistent, or the trials were undertaken in a 
population that differs from the target population of the recommendation.
C Nonrandomised trials. Evidence is from outcomes of uncontrolled or nonrandomised trials or from 
Observational studies observational studies.
D Panel consensus judgment This category is used only in cases where provision of some guidance was deemed 
valuable but an adequately compelling clinical literature addressing the subject of 
the recommendation was deemed insufficient to justify placement in one of the 
other categories. The Panel Consensus is based on clinical experience or 
knowledge that does not meet the above-listed criteria.
Table 1
Description of levels
of evidence.
tion on most days for at least three months a year
during at least two successive years) but does not
reflect the major impact of the airflow limitation
in COPD on mortality and morbidity. Emphy-
sema, the definition of which is based on pathol-
ogy (abnormal permanent enlargement of the air-
spaces distal to the terminal bronchioles, accom-
panied by destruction of the alveolar walls and
without obvious fibrosis) is often – but incorrectly
– used clinically, since it represents only a part of
the structural abnormalities present in COPD. A
variable mixture of inflammatory changes of large
and small airways and emphysema causes chronic
airflow limitation, which is the major characteris-
tic of COPD. 
Pathophysiology
The major risk factors for the development of
COPD are inhaled toxic substances – particularly
the inhalation of tobacco smoke – which cause in-
flammation of the lungs. The inflammation can
lead to tissue damage if the normal protective
and/or repair mechanisms are overwhelmed or
defective. The results of the lung tissue damage 
are mucus hypersecretion, airway narrowing and
fibrosis, destruction of the parenchyma and vas-
cular changes. These pathological changes lead 
to airflow limitation and the other physiological
abnormalities [8–10].
COPD is characterised by persistent inflam-
mation throughout the airways and parenchyma,
intensity and cellular characteristics, which vary 
as the disease progresses. Activated inflammatory
cells release products that are capable of damaging
lung structures. These cell products include pro-
teases, oxidants and toxic peptides. The inflamma-
tion in COPD is markedly different from that in
asthma. However, some patients with COPD also
have asthma, and the inflammation in their lungs
may show characteristics of both diseases.
Since inflammation is a feature of COPD,
anti-inflammatory therapies may have beneficial
effects in controlling symptoms, preventing exac-
erbations, and slowing disease progression. How-
ever, the response of inflammation to corticos-
teroids is poor in COPD, contrary to their effec-
tiveness in asthma [11]. The functional conse-
quences and therapeutic outlook depend on the
relative contribution of the following processes
[12]: 
– inflammatory narrowing and remodelling of
the bronchi and bronchioli;
– impaired mucociliary clearance;
– proteolytic digestion of the connective-tissue
framework of the lung, which results in de-
creased parenchymal tethering of the airways;
– loss of alveolar surface area and capillary bed;
– lung hyperinflation caused by loss of lung elas-
tic recoil and air trapping;
– increased pulmonary vascular resistance caused
by vasoconstriction and loss of capillary bed.
Risk factors
Risk factors for COPD include both host fac-
tors and environmental exposures, and the disease
arises from an interaction between these two [13].
Much of the evidence concerning risk factors for
COPD comes from cross-sectional epidemiologi-
cal studies which identify associations rather than
causal links. Cigarette smoking is the main identi-
fied risk factor for COPD, although non-smokers
may occasionally be affected. It is important to
note that currently no methods exist to predict
which smoker will develop COPD. Heavy expo-
sure to occupational dust (e.g. farming), indoor
pollution, low socioeconomic status and inherited
α-1 antitrypsin deficiency are recognised addi-
tional risk factors for COPD [14–16]. It is esti-
mated that α-1 antitrypsin deficiency is responsi-
ble for approximately 2% of all cases of emphy-
sema in the United States [17, 18]. Passive expo-
sure to environmental tobacco smoke, respiratory
infections and airway hyperresponsiveness may
also contribute [19].
Epidemiology and burden of disease
COPD is a leading cause of morbidity and
mortality worldwide [20–22]. COPD is under-
diagnosed and its social and economic burden on
patients and society are underestimated. Preva-
lence, morbidity, and mortality vary across coun-
tries, but in all regions, where data are available,
COPD is a significant public health problem in
both men and women. Prevalence data from the
United States indicate that COPD has been in-
creasing steadily over the past 20 years, with a
higher rate of increase in women than in men. In
the United Kingdom COPD affects 6% of men
and 4% of women aged over 45. In Switzerland the
prevalence of cough and chronic sputum is 3.1%,
whereas cough or sputum production is reported
in up to 16.7% of smokers, 7.5% of ex-smokers and
7.0% of never-smokers [23]. Today’s high pre-
valence of smoking among young adults and ado-
lescents in Switzerland is alarming and may in-
crease the burden of COPD in the years to come
[24]. It is estimated that at least 350 000 individu-
als in Switzerland have COPD.
COPD mortality is highest in east European
countries, Ireland, Scotland, and England [25]. In
the USA the age-adjusted mortality rate increased
by 17% in men, from 96.3 per 100 000 in 1979 to
112.8 per 100000 in 1993, whereas the rate in-
creased by 126% in women, from 24.5 per 100 000
in 1979 to 55.4 in 1993 [20, 26]. 
COPD is usually diagnosed late in its course,
because patients may be insensitive to airflow ob-
struction and lack symptoms even at low FEV1
[21]. 5-year survival in patients with severe COPD
(e.g. mean FEV1 of 49% predicted, mean age 66
years) was 47%, while 10-year survival was 23% in
spite of therapy [27]. The non-smoking population
shows a decline in FEV1 of approximately 20 ml/
year compared with an annual FEV1 decrease of
50–60 ml/year in smokers. The only proven way
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to slow down this course is smoking cessation [28]
(Evidence A). 
Assessment
Clinical assessment
A complete history and physical examination
should be performed in the initial assessment of
each patient suspected of having COPD. Short-
ness of breath due to COPD cannot be reliably dis-
tinguished from dyspnoea due to other causes. It
is frequently associated with cough, wheezes, spu-
tum production, and recurrent respiratory infec-
tions. Physical examination may reveal signs of
lung hyperinflation, increased respiratory muscle
effort, altered breathing patterns (i.e. increased
respiratory rate, prolonged expiration), and ab-
normal breath sounds. The accuracy of physical
examination to detect or exclude moderately se-
vere COPD is poor [3]. Since most patients with
COPD are cigarette smokers and usually belong to
an older age group, they often suffer from con-
comitant diseases such as coronary heart disease,
peripheral vascular disease etc. This must be con-
sidered in the diagnostic workup and for treatment
strategies. 
Pulmonary function testing 
In patients with symptoms of COPD or a his-
tory of exposure to risk factors, particularly ciga-
rette smoking, lung function should be tested.
Spirometry is the gold standard for assessment of
the presence and degree of airflow obstruction.
The abnormalities consist of a reduction in FEV1
and in the ratio of FEV1 to forced vital capacity
(FVC). Small spirometers, fulfilling the usual qual-
ity criteria are available at a reasonable cost. These
handheld spirometers are convenient to use, have
a graphic display, and store and print the numeric
results and flow-volume curve, i.e. the patient’s
spirogram. Office spirometry with such a device is
recommended for widespread use by primary care
physicians, particularly in smokers ≥45 years [29].
If COPD is detected at an early stage, successful
smoking cessation may prevent further disease
progression. In COPD the correlation between
peak expiratory flow (PEF) and FEV1 is poor.
Hence measurement of PEF, well established in
the management of asthma, should not be used in
patients with COPD. The severity of COPD is
classified on the basis of clinical signs and symp-
toms and the degree of airflow obstruction (see
table 2) [1]. This somewhat arbitrary staging sys-
tem is intended to standardise the grading of dis-
ease severity. 
COPD is frequently associated with an in-
crease in total lung capacity and residual volume
and with a reduction in diffusing capacity for car-
bon monoxide, which correlates with the degree of
emphysema. 
Arterial blood gas analysis should be per-
formed in patients with an FEV1 <50% predicted
or clinical signs of right heart failure. 
Chest x-ray and thoracic CT scan
A plain chest x-ray in posterior-anterior and
lateral projection may demonstrate the presence of
hyperlucency, vascular attenuation and hyperinfla-
tion, suggesting the presence of emphysema. A
chest radiograph is indicated as part of the initial
workup of patients with COPD to exclude con-
comitant pathologies. However, chest films are not
sensitive enough to detect emphysema. Computed
tomography (CT) in high-resolution technique is
the most sensitive and specific in vivo technique for
detection of pulmonary emphysema and grading
of its severity. While CT scanning is not recom-
mended for routine clinical assessment of COPD,
it may be used to evaluate the feasibility of lung
volume reduction surgery. 
Additional tests
The detection of erythrocytosis arouses suspi-
cion of chronic hypoxaemia. ECG changes sug-
gestive of cor pulmonale are insensitive but indi-
cate the need for arterial blood gas analysis. Mea-
surement of serum α-1 antitrypsin is indicated in
patients with early manifestations of emphysema.
Other laboratory investigations are indicated in
COPD patients in the presence of complications.
Quality of life assessment by questionnaire is a vali-
dated method of evaluating the effects of COPD
on everyday life and may be used to monitor the
course of the disease [30–32]. Six-minute walking
distance may be used to quantify global functional
impairment. Shortness of breath in patients with
COPD can be assessed by using the modified Med-
ical Research Council (mMRC) dyspnoea scale
[33, 34] (table 3).
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Stage characteristics
Mild (Stage I) • FEV1/FVC <70%
• FEV1 >80% predicted
Moderate (Stage II) • FEV1/FVC <70%
• 30% <FEV1 <80% predicted 
(II A: 50% ≤FEV1 <80% predicted)
(II B: 30% ≤FEV1<50% predicted) 
Severe (Stage III) • FEV1/FVC <70%
• FEV1 ≤30% predicted or FEV1 <50%
predicted with a PaO2 <8 kPa or clinical 
signs of right heart failure
Table 2
Classification of
severity of COPD.
0 No breathlessness except during strenuous exercise
1 Shortness of breath when hurrying on the level or up 
a slight rise
2 Walking more slowly than people of the same age on the 
level because of breathlessness or need to stop for breath 
when walking at own pace on the level
3 Stopping for breath after walking 100 metres or after a few 
minutes on the level
4 Too breathless to leave the house or breathlessness on 
dressing or undressing
Table 3
Modified Medical Re-
search Council Scale
(mMRC).
The objectives of COPD treatment are sum-
marised in table 4.
Prevention
Identification, reduction, and control of risk
factors to prevent the onset of COPD (primary
prevention) are important steps towards develop-
ing strategies for secondary prevention of COPD.
These factors include tobacco smoke, occupa-
tional exposure, indoor/outdoor pollution and ir-
ritants. In smokers, smoking cessation is the single
most effective way of reducing the risk of COPD
progression [35] (Evidence A). A brief advisory ses-
sion from a general practitioner results in smoking
cessation rates of  7.4%, i.e. an increase of  2.5%
over the cessation rate in control groups, and 3–10
minutes’ counselling achieves higher cessation
rates of approx. 12%. With greater investment of
time and complexity of interventions, including
skills training, problem solving and psychosocial
support, the quit rate may reach 20–30% [36] (Ev-
idence A). In the Lung Health Study, a multicen-
tre controlled clinical trial, a combination of physi-
cian advice, group support, skills training and nico-
tine replacement therapy achieved quit rates of
35% at one year and sustained quit rates of 22% at
5 years [37]. The following pharmacotherapies are
effective in supporting smoking cessation attempts
and at least one of these drugs should be prescribed
in the absence of contraindications: bupropion SR,
nicotine replacement in various galenic prepara-
tions [28, 38–42] (Evidence A).
Many occupational respiratory disorders (e.g.
in farmers) can be reduced or controlled by a vari-
ety of strategies aimed at reducing the burden of
inhaled particles and gases at the workplace [16]
(Evidence B).
Patient education
Studies suggest that education is effective in
accomplishing certain specific goals, including
smoking cessation [37] (Evidence A), initiation of
discussions and understanding of advanced direc-
tives and end-of-life issues [43] (Evidence B), and
improvement of patients’ responses to acute exac-
erbations [44] (Evidence B). 
Pharmacological treatment
None of the available drugs for COPD are ef-
fective in modifying the long-term progression of
airflow limitation that is the hallmark of this dis-
ease (Evidence A). Therefore, today’s polyphar-
macy, overuse, and overdose of drugs are a signif-
icant burden on the cost of COPD management. 
Bronchodilators
Bronchodilator drugs are central to the symp-
tomatic management of COPD. However, they do
not modify the decline of lung function or, by in-
ference, the prognosis of the disease (Evidence B).
They are given on an as-needed or regular basis to
prevent or reduce shortness of breath. 
Aerosol formulations are the preferred way of
administration. Attention to effective drug deliv-
ery and training in inhalation technique is essen-
tial. The use of metered dose inhalers (MDI) with
spacer devices, dry powder inhalers (DPI) or pos-
sibly nebulisers should be tailored to the patient’s
abilities. 
The choice between β2-agonists or anticholin-
ergics, or a combination therapy, depends on indi-
vidual symptomatic response. Long-acting inhaled
bronchodilators may be the most convenient for
continuous symptomatic relief. Slow-release xan-
thines are effective in COPD but are a second-line
choice due to their potential toxicity. They may be
added to regular inhaled bronchodilators in more
severe COPD.
Combining drugs whose mechanisms and du-
ration of action differ increases the degree of bron-
chodilatation and lessens the probability of side
effects [45, 46].
Anticholinergics: Inhibition of vagal stimulation
of the bronchial tree is associated with reduced
smooth muscle tone and bronchial gland secretion.
The bronchodilating effect of short-acting inhaled
anticholinergics lasts up to 8 hours after adminis-
tration [37, 47] (Evidence A). Extensive use of this
class of inhaled agents in a wide range of doses and
clinical settings has shown them to be very safe.
When administered via metered dose inhaler
(MDI), the recommended dose of ipratropium
bromide is 2–4 puffs (40–80 µg) 4 times daily. For
severe exacerbations, the dosage may be increased,
e.g. MDI with spacer 6–8 puffs every 3–4 h or neb-
ulised ipratropium 0.5 mg every 4–8 hours (0.5 mg
corresponds to 40 gtts. of a 0.25% solution) [48].
More recently several studies have reported
favourable effects with tiotropium, a new long-act-
ing anticholinergic bronchodilator which must be
inhaled only once daily [49, 50].
Beta-2-agonists: Beta-2-agonists are useful for 
patients with reversible airway obstruction and for
patients with dyspnoea or cough, even under max-
imal anticholinergic inhalation therapy. Because of
their rapid onset of action, beta-2-agonists (such
as salbutamol, terbutaline or formoterol) can be
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Management of COPD
Relief of symptoms
Improvement of exercise tolerance
Improvement in health status
Improvement in quality of life
Prevention of disease progression
Prevention and treatment of complications
Prevention and treatment of exacerbations
Reduction in mortality due to respiratory illness
Table 4
Objectives of man-
agement for COPD.
used as rescue medication in cases of bron-
chospasm. The bronchodilator effect of short-act-
ing beta-agonists usually disappears within 4–6
hours. For severe exacerbations it is acceptable to
increase the number of puffs and to shorten the in-
terval between puffs from MDI or DPI by up to
3–4 hours, provided it is for short periods of time.
Since sympathomimetic bronchodilators protect
against bronchospasm induced by various stimuli
and reduce dynamic hyperinflation during physi-
cal exercise, they may reduce dyspnoea even if they
do not improve FEV1 [51].
The effect of long-acting inhaled β2-agonists
(salmeterol and formoterol) in COPD patients is
maintained over 12 hours with no loss of effec-
tiveness overnight or during regular use [52, 53]
(Evidence B). The effectiveness of long-acting in-
haled β2-agonists in COPD has not been studied
enough to allow a general recommendation for
their use in COPD patients. However, 50 µg sal-
meterol twice daily reduces breathlessness and im-
proves quality of life [54]. Formoterol brings about
long-lasting functional improvement in appar-
ently poorly reversible chronic pulmonary disease
[55] (Evidence B). The degree of improvement in
airway function does not correlate with subjective
symptomatic improvement [56]. 
Salmeterol has an effect on exercise-induced
dyspnoea comparable to ipratropium for up to 6
hours after administration [57]. Furthermore, this
long-acting beta-2-agonist was superior to theo-
phylline alone with respect to lung function and
symptom control [58, 59]. Cumulative use of mul-
tiple forms of beta-2-adrenergics does not enhance
their effectiveness but increases the risk of side ef-
fects and should therefore be avoided. However,
some patients with COPD may benefit from a
combination of salmeterol or formoterol plus ipra-
tropium or theophylline without a resultant in-
crease in adverse effects [58, 60, 61].
Theophylline: Theophylline acts as a non-se-
lective phosphodiesterase inhibitor. Besides bron-
chodilatation, theophylline shows various physio-
logic actions such as increased central respiratory
drive, mucociliary clearance, respiratory muscle
endurance, cardiac output, and dilatation of pul-
monary arteries [62].
Theophylline is given orally at a low dose and
in a sustained-release formulation for administra-
tion once or twice a day. Its use may be considered
when inhaled therapy fails to produce adequate
bronchodilatation or when patients have noctur-
nal respiratory symptoms. The therapeutic index
of theophylline is narrow. Toxicity is characterised
by wide individual differences due to variations in
metabolism and drug interactions, which restrict
its utility. Several studies have recently been
started with cilomilast, a selective phosphodi-
esterase-4 inhibitor. Its potential therapeutic ac-
tions include bronchodilatation and effects on in-
flammation and neuromodulation without major
adverse events [63].
Glucocorticosteroids 
When considering the position of glucocorti-
costeroids in the management of COPD, their role
during exacerbations and during stable phases of
COPD (steroid trial) should be distinguished. 
The effects of glucocorticosteroids on airway
inflammation in COPD are much less pronounced
than in asthma. Based on the lack of evidence of 
a long-term beneficial effect of chronic oral glu-
cocorticoid therapy in subjects with confirmed
COPD, and a large body of evidence on the long-
term adverse effects of this treatment, including
the contribution of steroid myopathy to respira-
tory failure in COPD, chronic treatment with oral
glucocorticosteroids should not be used in COPD
[64–68] (Evidence A). There is strong evidence
that prolonged treatment with inhaled glucocorti-
costeroids does not modify the long-term decline
in FEV1 in patients with COPD. 
Steroid trial: Many recent COPD guidelines
recommend the use of a short course (two weeks)
of oral glucocorticoids (e.g. 0.5 mg prednisone or
prednisolone/kg body weight) to identify patients
who respond favourably and hence may benefit
from long-term treatment with inhaled glucocor-
ticosteroids. However, a short course of oral glu-
cocorticosteroids is not a very reliable predictor 
of the long-term response to inhaled glucocorti-
costeroids in COPD [69]. Nevertheless, patients
with symptomatic obstruction to airflow qualify
for a therapeutic trial with systemic glucocorti-
costeroids. The response to the trial should be
assessed by spirometry to identify patients with
significantly reversible airways obstruction (i.e. an
increase in FEV1 >200 ml and >12–15% from 
postbronchodilator baseline measurements), who
should be identified in order to detect a compo-
nent of associated bronchial asthma [70]. The re-
sults of a steroid trial can only be assessed in a sta-
ble phase of the disease, at least 6 weeks after an
exacerbation and on the basis of repetitive and re-
producible measurements of the patient’s FEV1. 
Inhaled glucocorticosteroids: Recent studies on
the long-term effects of inhaled corticosteroids in
COPD have shown only minimal effect, despite
relatively high dosages [71–74]. The annual de-
cline of FEV1 did not change in mild COPD
(budesonide 1200 µg/d for 6 months followed by
800 µg for the remaining 30 months or triamci-
nolone 1200 µg/d for 40 months). In more severe
COPD, inhaled steroids improved the FEV1 dur-
ing the first 3 months but the decline thereafter
was not modified (budesonide 800 µg/d for three
years, fluticasone 1000 µg/d for three years). Other
outcome variables such as respiratory symptoms or
number of annual exacerbations were positively
modified in some studies. In the ISOLDE study,
fluticasone treatment significantly reduced the
number of exacerbations and slowed the loss of
quality of life in patients with advanced COPD
(FEV1 <50% predicted).
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The formulation of topical steroids (budeso-
nide, fluticasone, triamcinolone) is probably not
important. The dose-response relationship or the
therapeutic effect of inhaled corticosteroids in
COPD and their safety during long-term use are
not known. Similar adverse effects to those in
asthma can be expected in COPD, depending on
the dose and type of glucocorticosteroid. There is
a need for further documentation in this popula-
tion. Some studies have shown an increased inci-
dence of skin bruising [73, 74]. Bone deminerali-
sation was observed in one study [75]. The eco-
nomic consequences of regular use of inhaled
steroids should be evaluated in future cost-benefit
studies.
On the basis of these data, regular treatment
with inhaled corticosteroids should only be con-
sidered for symptomatic patients with advanced
COPD suffering from repeated exacerbations
[76–78] (Evidence B).
Antibiotics 
The use of antibiotics, other than to treat in-
fectious exacerbations, is not recommended [79].
Mucolytics
The regular use of mucolytics in COPD has
been evaluated in a number of long-term studies
with controversial results. The majority showed no
effect of mucolytics on lung function or symptoms,
although some reported a reduction in the fre-
quency of acute exacerbation [80]. Although a few
patients with viscous sputum may benefit from
mucolytics, the widespread use of these agents can-
not be recommended [81] (Evidence D). Effects of
beta-2-adrenergics or theophylline on mucociliary
clearance are minor but welcome additional effects
partly mediated by bronchodilatation. 
N-acetylcysteine 
Oral N-acetylcysteine (NAC) in a daily dose
of 400–600 mg for 3–6 months reduces the risk of
exacerbations and improves symptoms in patients
with chronic bronchitis compared with placebo.
NAC is well tolerated and has no relevant side ef-
fects [82] (Evidence B). An ongoing multicentre
study will shortly provide additional data on
NAC’s effects on the decline in FEV1, exacerbation
rate, quality of life and cost-utility [83].
Immunoregulators
Immunostimulating agents made from bacte-
rial extracts represent a class of medication whose
potential benefit results from nonspecific stimula-
tion of the immune system. OM-85 BV is an im-
munostimulating agent made from eight different
species of bacteria that are frequently present in
the lower respiratory tract. A study using OM-85
BV showed beneficial effects in patients with
COPD by lessening the likelihood of severe respi-
ratory events leading to hospitalisation [84, 85] (Ev-
idence B).
Respiratory stimulants
Doxapram, a nonspecific respiratory stimulant
available as an intravenous formulation, is not rec-
ommended in stable COPD (Evidence D). Due to
its potential neurological side effects almitrine
bismesylate is not recommended in the treatment
of COPD patients [86] (Evidence B).
The carboanhydrase inhibitor acetazolamide
should no longer be used in patients with hyper-
capnic respiratory failure.
Vaccination
Influenza vaccination
Influenza vaccination reduces serious illness
and death in COPD patients by approximately
50% [87]. Most fatalities from influenza result
from secondary bacterial pneumonia, which leads
to respiratory failure [88]. Immunisation should be
performed once in autumn of each year or twice
autumn/winter (Evidence A).
Pneumococcal vaccine
A pneumococcal vaccine containing epitopes
from 23 virulent strains has been proposed for
COPD patients to prevent pneumococcal infec-
tion. It has been shown that about 50% of invasive
pneumococcal infections could be prevented by
the vaccination. Since 1997 the Advisory Com-
mittee on Immunisation Practices has recom-
mended the vaccination in COPD patients, par-
ticularly those over 64 [89] (Evidence B).
Haemophilus influenzae vaccine
Oral vaccination, in the autumn, of patients
with recurrent exacerbations of bronchitis reduces
the number and severity of exacerbations over the
winter months [90] (Evidence B). The whole cell
non-typable Haemophilus influenzae (NTHi) vac-
cine is not yet available in Switzerland. 
Oxygen therapy
It has been conclusively shown that the sur-
vival of patients with COPD-induced hypoxaemia
is improved by long-term O2 therapy, and that the
benefit is greatest if the treatment is administered
for at least 15–18 h/day [91–94] (Evidence A). 
Long-term oxygen therapy [95] is indicated if
the PaO2 is:
– at or below 7.3 kPa (55 mm Hg) with or with-
out hypercapnia
– between 7.3 kPa (55 mm Hg) and 8.0 kPa (59
mm Hg), if symptoms or signs of right heart
failure and/or erythrocytosis are present. 
The primary goal of oxygen therapy is to in-
crease the baseline arterial partial pressure (PaO2)
to at least 8.0 kPa (60 mm Hg) or to achieve arte-
rial oxygen saturation equal to or above 90%.
Samples for arterial blood gas measurement
should be obtained by arterial puncture. 
In the absence of sleep apnoea symptoms there
is no indication for specific sleep studies.
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Prescription of oxygen should always include
the source of supplemental oxygen (gas or liquid),
the method of delivery (nasal cannula, transtra-
cheal), duration of use (hours per day), and the flow
rate at rest, during exercise and sleep. Oxygen
given during exercise may increase walking dis-
tance and endurance, most probably by optimising
oxygen delivery to tissues and its utilisation by
muscles. However, there are no data to suggest that
long term oxygen therapy changes exercise capac-
ity per se. This treatment is usually restricted to pa-
tients who meet criteria for continuous oxygen or
experience significant oxygen desaturation during
exercise (Evidence C).
Alpha-1-antitrypsin replacement 
Augmentation therapy with α1-antitrypsin in-
creases α1-antitrypsin levels and anti-elastase ac-
tivity in serum and bronchoalveolar lavage fluid.
Patients with documented severe deficiency and
established emphysema who have stopped smok-
ing may be considered candidates for this therapy.
However, intravenous substitution therapy is ex-
pensive and its benefits have not been confirmed
in a prospective randomised trial [96–100] (Evi-
dence D). 
Ventilatory support
While several studies have confirmed the use-
fulness of non-invasive ventilation during acute ex-
acerbations by avoiding intubation and decreasing
short-term mortality [101, 102], the role of non-
invasive ventilation in the long-term management
of COPD patients at home is controversial [103,
104]. Uncontrolled studies suggest that it de-
creases the rate of hospital admissions in hyper-
capnic COPD patients with frequent exacerba-
tions [105].
Pulmonary rehabilitation
The components of pulmonary rehabilitation
vary widely from one institution to another but a
comprehensive pulmonary rehabilitation pro-
gramme should include exercise training, nutrition
counselling and education. All patients, irrespec-
tive of their degree of disability, benefit from ex-
ercise training programmes (Evidence A). The
type of exercise (stair climbing, walking, treadmill,
or bicycle ergometer) may vary and is best deter-
mined by patient preference and cost. The exer-
cises should aim at training all parts of the muscu-
loskeletal system, especially the muscles of the
back and the upper extremities. Whether pul-
monary rehabilitation is carried out in an in- or
outpatient programme depends on local availabil-
ity and patients preference. After structured reha-
bilitation the patient should continue with regular
exercises at home and preferably participate in a
guided outpatient group [106–113].
Scientific evidence does not support the rou-
tine use of respiratory muscle training; it may be
considered for individual patients [106, 114] (Evi-
dence B).
Psychosocial support 
By natural history COPD is a progressive dis-
ease which will eventually severely impair quality
of life. Even with the best pharmacological care,
shortness of breath, already occurring during daily
activities, profoundly modifies family life, sexual-
ity, and social interaction. The patient becomes
more isolated, dependent, and full of grief. This
complex burden of suffering can be overwhelming.
The patient’s coping mechanisms may be insuffi-
cient. This is a challenging disease for the physi-
cian in charge as well as for other health care work-
ers. 
As in other chronic diseases, the medical ap-
proach should be “patient-centred” and should
leave enough time for the patient to express his or
her subjective suffering [115]. Severe chronic ill-
ness such as advanced COPD requires all the car-
ing physician’s medical and human resources [116,
117]. The use of anxiolytic or antidepressive agents
may be helpful. Participation in support groups
should be encouraged.
Nutrition 
Weight loss is a common feature in patients
with advanced COPD. The clinical importance of
weight loss, particularly of fat-free mass (FFM),
and its adverse effects on physical performance and
quality of life has been demonstrated [118]. More-
over, a low body mass index (BMI) is an inde-
pendent predictor for increased mortality [119]. 
Although nutritional support in these patients
seems logical, controlled trials have not shown sig-
nificant effects of weight gain on lung function or
exercise capacity in patients with stable COPD
[120–125].
Anabolic steroids and growth hormones
Some studies using anabolic steroids such as
nandrolone decanoate or stanozolol [126] as a
component of a training programme [122] have
shown an increase in free fat mass and improve-
ment in respiratory muscle strength. However,
there is insufficient evidence to support the use of
these drugs in the treatment of COPD patients
(Evidence B).
Preliminary reports suggest that nitrogen bal-
ance in COPD patients may be improved by
growth hormone therapy [127, 128]. However,
daily administration of recombinant growth hor-
mone increases lean body mass but does not im-
prove muscle strength or exercise tolerance in un-
derweight patients with COPD [129].
Surgical approaches 
Lung volume reduction surgery 
Bullectomy i.e. the removal of large bulla com-
pressing the adjacent lung structures is effective in
reducing dyspnoea and improving lung function
[130] (Evidence B). Lung volume reduction sur-
gery (LVRS) is a palliative procedure which not
only improves pulmonary function and exercise
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capacity in selected patients with severe hyperin-
flation, but has a major positive impact on quality
of life for several years [131–134]. Patients with
heterogeneous types of emphysema show the
greatest improvement in pulmonary function after
LVRS [135–142].
Lung transplantation
In appropriately selected patients with very ad-
vanced COPD and an estimated life expectancy
below 6–18 months (FEV1 <25% predicted, PaO2
<55–60 mm Hg, hypercapnia, secondary pul-
monary hypertension, 6´ walking distance <250 m)
unilateral or bilateral lung transplantation has the
potential to improve quality of life and functional
capacity [143, 144]. Contraindications for this
treatment, which makes lifelong immunosuppres-
sion mandatory, are malignancies, generalised
arteriosclerosis, renal failure or liver failure, drug
abuse, and emotional instability. 
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Management of acute exacerbations
Exacerbations of respiratory symptoms re-
quiring medical intervention are important clini-
cal events in COPD. The most common causes of
an exacerbation are viral and bacterial bronchial
infections and peaks of air pollution [145–147], but
in about one-third of severe exacerbations the
cause cannot be identified. 
There is no widely accepted definition of acute
exacerbation in COPD, but most published defi-
nitions encompass a combination of three clinical
findings: worsening of dyspnoea, increase in spu-
tum purulence, and increase in sputum volume. 
Bronchodilators
Home management of COPD exacerbation
involves increasing the dose and/or frequency of
already established bronchodilator therapy (Evi-
dence A), particularly inhaled β2-agonists or/and
anticholinergics. Some patients experience addi-
tional benefit when a second inhaled bronchodi-
lating agent is administered after the maximum
dose of the initial agent is reached. 
The efficacy of wet nebulisation and dry
aerosol delivery systems (meter-dose inhaler plus
spacer or powder) are probably clinically equiva-
lent [148]. Hence the choice of a specific delivery
method should be determined on an individual
basis, depending on each patient’s ability to use the
various methods.
Corticosteroids
Systemic, preferably oral glucocorticosteroids
are beneficial in the management of acute COPD
exacerbations (Evidence A). They shorten recov-
ery time, restore lung function more quickly, and
may decrease the need for hospitalisations. Several
studies have shown that treatment with oral or i.v.
corticosteroids improves the rate of lung function
more rapidly during the first 72 hours of an exac-
erbation. There is no evidence that this benefit is
maintained beyond 72 hours, or that other out-
comes, such as re-hospitalisation rate, are im-
proved [149, 150]. Dosage and length of treatment
vary greatly among studies. An oral dose of 40 mg
prednisolone (or equivalent), for not more than 2
weeks, can be recommended [151] (Evidence D).
Tapering of corticosteroids is not necessary
following short-term administration. Hypergly-
caemia is the most common adverse effect associ-
ated with systemic corticosteroids for acute exac-
erbation of COPD.
There is no data on the use of intramuscular
depot steroids in the therapy of COPD exacerba-
tions. Inhaled steroids are not appropriate in acute
exacerbation of COPD.
Antibiotics
COPD exacerbations with clinical signs of
airway infection benefit from antibiotic treatment
[152, 153] (Evidence B). Because Haemophilus in-
fluenzae, Streptococcus pneumoniae and Branhamella
catarrhalis are most frequently associated with
COPD exacerbation, the antibiotics used should
be directed preferentially against these bacteria
[154, 155]. Commonly used antibiotics include
amoxicilline and clavulanic acid, trimethoprim-
sulfamethoxazole, macrolides and quinolones. Be-
cause of the reported increase in resistant bacter-
ial strains it has become common practice to use
broader-spectrum antibiotics. However, to date no
randomised, placebo-controlled trials have proved
the superiority of the newer broad-spectrum an-
tibiotics in this scenario.
Studies show that patients with more severe
exacerbations are more likely to experience bene-
fit from antibiotics. Typical administration periods
ranged from 3 to 14 days. 
Hospital admission
Although most acute exacerbations can be
treated on an outpatient basis, some patients re-
quire hospitalisation or treatment in an emergency
room.
Indications for hospitalisation for acute exac-
erbation of COPD:
– increase in symptom intensity 
– failure to respond to initial medical manage-
ment
– severe COPD
– respiratory failure
– significant co-morbidity
– older age
– mental confusion
– insufficient home support
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